# VitaFlowTM II Transcatheter Aortic Valve System Study

Study · id `cardio:ct-nct03575039` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03575039](<https://clinicaltrials.gov/study/NCT03575039>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03575039

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 178 participants.

## Technical summary

Registry record NCT03575039. Allocation not applicable; no masking; primary purpose treatment. Start 2018-08 (anticipated); primary completion 2020-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 178 participants (planned count; ClinicalTrials.gov record NCT03575039, source copy `cardio:ctgov-nct03575039-2018-07-02`, retrieved 2026-10-26)
- Planned start: 2018-08 (anticipated) (ClinicalTrials.gov record NCT03575039, source copy `cardio:ctgov-nct03575039-2018-07-02`, retrieved 2026-10-26)
- Primary completion: 2020-12 (anticipated) (ClinicalTrials.gov record NCT03575039, source copy `cardio:ctgov-nct03575039-2018-07-02`, retrieved 2026-10-26)
- Completion: 2024-12 (anticipated) (ClinicalTrials.gov record NCT03575039, source copy `cardio:ctgov-nct03575039-2018-07-02`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03575039-2018-07-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: VitaFlowTM II Transcatheter Aortic Valve System Study
- Condition: Aortic Valve Stenosis
- Intervention (Device): VitaFlow II Transcatheter Aortic Valve System
- Lead sponsor: Shanghai MicroPort CardioFlow Medtech Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Shanghai MicroPort CardioFlow Medtech Co., Ltd. (`cardio:org-shanghai-microport-cardioflow-medtech-co-ltd`)

## Provenance

Content hash: bbe0b61f8744d3235d67b03c27a6a2a7ef9fc128845e2d9d137ad8e93fa2098d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
